Segment & Geographic Data
Quant-Grade Normalized (live API)
API & CSV Delivery
Insmed Inc's Business Segments
Insmed Inc's reported revenue by business segment and by geographic region, quarterly and annual, normalized against the consolidated income statement. Free below: the top 3 rows per table, this quarter and this fiscal year. Subscriber access adds the full segment history and operating income by segment.
Segment Data As of Q1 FY2026
Reportable Segments
1
Largest Segment
Reportable
Total Revenue
$ 286
Regions Reported
1
Revenue Share by Reportable Segment - Q1 FY2026
- Reportable0%
Revenue by Reportable Segment - Q1 FY2026
| Segment | Revenue (Millions) | % of Total |
|---|---|---|
| Reportable | $ 306 | - |
Revenue Share by Region - Q1 FY2026
- Non-US12.6%
Revenue by Geographic Region - Q1 FY2026
| Region | Revenue (Millions) | % of Total |
|---|---|---|
| Non-US | $ 36 | 12.6% |
Revenue by Product & Service Category - Q1 FY2026
- BRINSUPRI72.5%
- ARIKAYCE22%
Revenue by Product & Service Category - Q1 FY2026
| Category | Revenue (Millions) | % of Total |
|---|---|---|
| BRINSUPRI | $ 207 | 72.5% |
| ARIKAYCE | $ 63 | 22% |
Product and service categories are a supplemental disclosure and are not required to sum to consolidated revenue or to the reportable segments above.
Description of Insmed Inc
Insmed Inc. is a biopharmaceutical company that develops and commercializes innovative therapies for patients with unmet medical needs. The company was founded in 1988 and is headquartered in Bridgewater, New Jersey.
Insmed is focused on developing therapies for serious respiratory diseases and rare diseases that have limited treatment options. The company's lead product, ARIKAYCE, is the first and only FDA-approved therapy for patients with Mycobacterium avium complex (MAC) lung disease, a rare and chronic infection that can cause significant damage to the lungs.
The company's pipeline includes several other novel product candidates in various stages of development. INS1007 is being developed for the treatment of non-cystic fibrosis bronchiectasis, a chronic and debilitating respiratory disease. INS1009 is being developed for the treatment of rare pulmonary diseases, including pulmonary alveolar proteinosis and alpha-1 antitrypsin deficiency.
Insmed is also developing therapies for rare diseases outside of the respiratory space. The company's pipeline includes INS1001, a potential treatment for rare genetic disorders, including Pantothenate kinase-associated neurodegeneration (PKAN) and other pantothenate kinase-associated disorders.
The company has a strong commitment to research and development and invests heavily in this area. Insmed has a global team of scientists and researchers who are dedicated to discovering and developing new therapies for patients in need.
Insmed has experienced significant growth in recent years, with a market cap of over $5 billion as of early 202 The company has a strong financial position, with a cash and cash equivalents balance of $499 million as of September 30, 2020.
Overall, Insmed is a leading biopharmaceutical company focused on developing and commercializing innovative therapies for serious respiratory diseases and rare diseases. The company has a strong commitment to research and development and is well-positioned for continued growth and success in the biopharmaceutical industry.
Insmed is focused on developing therapies for serious respiratory diseases and rare diseases that have limited treatment options. The company's lead product, ARIKAYCE, is the first and only FDA-approved therapy for patients with Mycobacterium avium complex (MAC) lung disease, a rare and chronic infection that can cause significant damage to the lungs.
The company's pipeline includes several other novel product candidates in various stages of development. INS1007 is being developed for the treatment of non-cystic fibrosis bronchiectasis, a chronic and debilitating respiratory disease. INS1009 is being developed for the treatment of rare pulmonary diseases, including pulmonary alveolar proteinosis and alpha-1 antitrypsin deficiency.
Insmed is also developing therapies for rare diseases outside of the respiratory space. The company's pipeline includes INS1001, a potential treatment for rare genetic disorders, including Pantothenate kinase-associated neurodegeneration (PKAN) and other pantothenate kinase-associated disorders.
The company has a strong commitment to research and development and invests heavily in this area. Insmed has a global team of scientists and researchers who are dedicated to discovering and developing new therapies for patients in need.
Insmed has experienced significant growth in recent years, with a market cap of over $5 billion as of early 202 The company has a strong financial position, with a cash and cash equivalents balance of $499 million as of September 30, 2020.
Overall, Insmed is a leading biopharmaceutical company focused on developing and commercializing innovative therapies for serious respiratory diseases and rare diseases. The company has a strong commitment to research and development and is well-positioned for continued growth and success in the biopharmaceutical industry.
Insmed Inc. is a biopharmaceutical company dedicated to the discovery, development, and commercialization of therapies aimed at treating serious and rare diseases, particularly those with significant unmet medical needs. The company structures its offerings into distinct segments, products, and services that cater to the complex requirements of patients globally. Heres an extensive overview of each segment, product, and service offered by Insmed:
Segments
1. ARIKAYCE Segment: This segment is centered around ARIKAYCE, which is involved in the development and commercialization of inhaled liposomal amikacin. This therapy is specifically designed for the treatment of patients diagnosed with nontuberculous mycobacterial lung disease (NTM-LD), particularly focusing on infections caused by the Mycobacterium avium complex (MAC). The inhaled formulation is intended for patients who are unable to achieve adequate control of their infection with traditional treatment options.
2. INS1007 Segment: INS1007 represents Insmeds portfolio of novel, proprietary orally available inhibitors aimed at dipeptidyl peptidases (DPPs). This segment targets the treatment of serious inflammatory diseases. Through the inhibition of DPP enzymes, Insmed seeks to modulate the immune response and inflammation, thus offering potential new treatment options for patients suffering from conditions such as rheumatoid arthritis or systemic lupus erythematosus.
3. INS1009 Segment: This segment includes the development of INS1009, a potential treatment specifically formulated for rare autoimmune diseases. It focuses on conditions such as generalized myasthenia gravis (gMG) and focal segmental glomerulosclerosis (FSGS). INS1009 functions as a small-molecule inhibitor targeting the C5a receptor (C5aR), which plays a critical role in the pathophysiology of various autoimmune diseases by mediating inflammatory responses.
Products
1. ARIKAYCE (amikacin liposome inhalation suspension): ARIKAYCE is a groundbreaking product as it is the first and only FDA-approved treatment for Mycobacterium avium complex lung disease as part of a combination antibacterial drug regimen. This treatment is pivotal for adult patients who have limited or no alternative options available to them, significantly improving the management of MAC lung disease.
2. INS1007: This investigational product is an innovative small molecule designed to inhibit DPP1 and DPP2, with promising anti-inflammatory properties. It is currently under development for treating a variety of serious inflammatory conditions, positioning itself as a potential new line of treatment that could complement existing therapies.
3. INS1009: INS1009 is another investigational product aimed at addressing rare autoimmune diseases. As a small molecule inhibitor of the C5a receptor, it targets key pathways involved in immune dysregulation. This product is formulated to address the specific needs of patients suffering from gMG and FSGS, with an emphasis on providing new hope for treatment in this challenging therapeutic area.
Services
1. Medical Education: Insmed is committed to enhancing the knowledge and skills of healthcare providers through accredited educational programs. These educational activities are designed to keep providers informed about the latest treatment options, disease states, and best practices, which ultimately aims to improve patient outcomes.
2. Patient Support: Insmed offers a comprehensive suite of patient support services designed to assist individuals throughout their treatment journey. These services include financial assistance programs to alleviate the burden of treatment costs, patient education resources to empower patients with knowledge about their conditions and therapies, and nursing support for ongoing care and guidance.
3. Clinical Trials: As part of its commitment to innovation, Insmed actively conducts clinical trials to assess the safety and efficacy of its investigational products across various disease states. The company collaborates with academic institutions, researchers, and patients to drive research and development forward, aiming to find effective solutions for unmet medical needs.
Conclusion
In summary, Insmed Inc. offers a multifaceted portfolio of products and services tailored to address the significant unmet medical needs of patients suffering from serious and rare diseases. By focusing on innovative therapies, extensive medical education, robust patient support, and active engagement in clinical research, Insmed remains dedicated to improving the lives of patients on a global scale. Through its ongoing efforts, the company aims to provide hope and solutions where they are most needed in the healthcare landscape.
Segments
1. ARIKAYCE Segment: This segment is centered around ARIKAYCE, which is involved in the development and commercialization of inhaled liposomal amikacin. This therapy is specifically designed for the treatment of patients diagnosed with nontuberculous mycobacterial lung disease (NTM-LD), particularly focusing on infections caused by the Mycobacterium avium complex (MAC). The inhaled formulation is intended for patients who are unable to achieve adequate control of their infection with traditional treatment options.
2. INS1007 Segment: INS1007 represents Insmeds portfolio of novel, proprietary orally available inhibitors aimed at dipeptidyl peptidases (DPPs). This segment targets the treatment of serious inflammatory diseases. Through the inhibition of DPP enzymes, Insmed seeks to modulate the immune response and inflammation, thus offering potential new treatment options for patients suffering from conditions such as rheumatoid arthritis or systemic lupus erythematosus.
3. INS1009 Segment: This segment includes the development of INS1009, a potential treatment specifically formulated for rare autoimmune diseases. It focuses on conditions such as generalized myasthenia gravis (gMG) and focal segmental glomerulosclerosis (FSGS). INS1009 functions as a small-molecule inhibitor targeting the C5a receptor (C5aR), which plays a critical role in the pathophysiology of various autoimmune diseases by mediating inflammatory responses.
Products
1. ARIKAYCE (amikacin liposome inhalation suspension): ARIKAYCE is a groundbreaking product as it is the first and only FDA-approved treatment for Mycobacterium avium complex lung disease as part of a combination antibacterial drug regimen. This treatment is pivotal for adult patients who have limited or no alternative options available to them, significantly improving the management of MAC lung disease.
2. INS1007: This investigational product is an innovative small molecule designed to inhibit DPP1 and DPP2, with promising anti-inflammatory properties. It is currently under development for treating a variety of serious inflammatory conditions, positioning itself as a potential new line of treatment that could complement existing therapies.
3. INS1009: INS1009 is another investigational product aimed at addressing rare autoimmune diseases. As a small molecule inhibitor of the C5a receptor, it targets key pathways involved in immune dysregulation. This product is formulated to address the specific needs of patients suffering from gMG and FSGS, with an emphasis on providing new hope for treatment in this challenging therapeutic area.
Services
1. Medical Education: Insmed is committed to enhancing the knowledge and skills of healthcare providers through accredited educational programs. These educational activities are designed to keep providers informed about the latest treatment options, disease states, and best practices, which ultimately aims to improve patient outcomes.
2. Patient Support: Insmed offers a comprehensive suite of patient support services designed to assist individuals throughout their treatment journey. These services include financial assistance programs to alleviate the burden of treatment costs, patient education resources to empower patients with knowledge about their conditions and therapies, and nursing support for ongoing care and guidance.
3. Clinical Trials: As part of its commitment to innovation, Insmed actively conducts clinical trials to assess the safety and efficacy of its investigational products across various disease states. The company collaborates with academic institutions, researchers, and patients to drive research and development forward, aiming to find effective solutions for unmet medical needs.
Conclusion
In summary, Insmed Inc. offers a multifaceted portfolio of products and services tailored to address the significant unmet medical needs of patients suffering from serious and rare diseases. By focusing on innovative therapies, extensive medical education, robust patient support, and active engagement in clinical research, Insmed remains dedicated to improving the lives of patients on a global scale. Through its ongoing efforts, the company aims to provide hope and solutions where they are most needed in the healthcare landscape.